NASDAQ: SLSSellas Life Sciences Group Inc Stock
$1.52-0.02 (-1.3%)
Updated Apr 25, 2024
SLS Price
$1.52
Fair Value Price
$0.06
Market Cap
$85.53M
52 Week Low
$0.50
52 Week High
$1.91
P/E
-1.13x
P/B
-10.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.78
Operating Cash Flow
-$31M
Beta
0.92
Next Earnings
Jun 19, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SLS Overview
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLS ($1.52) is overvalued by 2,349.03% relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLS ($1.52) is not significantly undervalued (2,349.03%) relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLS due diligence checks available for Premium users.
Be the first to know about important SLS news, forecast changes, insider trades & much more!
SLS News
Valuation
SLS fair value
Fair Value of SLS stock based on Discounted Cash Flow (DCF)
Price
$1.52
Fair Value
$0.06
Overvalued by
2,349.03%
SLS ($1.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLS ($1.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.13x
Industry
15.41x
Market
40.97x
SLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-10.72x
Industry
5.8x
SLS's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.1M
Profit Margin
0%
SLS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.2M
Liabilities
$14.2M
Debt to equity
-1.78
SLS's short-term liabilities ($13.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLS's short-term assets ($3.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$0.0
Financing
$3.4M
SLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLS vs Biotech Stocks
Sellas Life Sciences Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.